Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time

Annual Review of Pathology: Mechanisms of Disease

Volumn 11, Issue , 2016, Pages 497-521

  Filbin, Mariella G ^a,b,c   Suvà, Mario L ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Histone mutations; IDH1; Oligodendroglioma

Indexed keywords

ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER STEM CELL; CHROMOSOME 19Q; CHROMOSOME 1P; EPIGENETICS; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; GENOMICS; GLIOBLASTOMA; GLIOMA; HUMAN; OLIGODENDROGLIOMA; PATHOGENESIS; PRIORITY JOURNAL; BRAIN TUMOR; GENETICS;

BRAIN NEOPLASMS; EPIGENOMICS; GENOMICS; GLIOMA; HUMANS;

EID: 84971281668     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012615-044208     Document Type: Article

References (145)

1. Bailey P, Cushing H. 1926. A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis. Philadelphia: Lippincott
2. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, et al. 2014. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 24:429-35
3. Stupp R, Mason WP, van den Bent MJ,WellerM, Fisher B, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987-96
4. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, et al. 2014. Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370:709-22
5. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, et al. 2014. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370:699-708
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-92
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-16
8. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-37
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-39
10. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363:1693-703
11. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, et al. 2015. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 372:2481-98
12. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, et al. 2012. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26:756-84
13. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, et al. 2013. The somatic genomic landscape of glioblastoma. Cell 155:462-77
14. Sugawa N, Ekstrand AJ, James CD, Collins VP. 1990. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. PNAS 87:8602-6
15. Schwechheimer K, Huang S, Cavenee WK. 1995. EGFR gene amplification-rearrangement in human glioblastomas. Int. J. Cancer 62:145-48
16. BiernatW,Huang H, YokooH, Kleihues P, OhgakiH. 2004. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 14:131-36
17. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. 1998. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J. Neurovirol. 4:148-58
18. Furnari FB, Cloughesy TF, Cavenee WK,Mischel PS. 2015. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat. Rev. Cancer 15:302-10
19. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, et al. 2011. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810-17
20. Francis JM, Zhang CZ, Maire CL, Jung J, Manzo VE, et al. 2014. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 4:956-71
21. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, et al. 2014. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396-401
22. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, et al. 2013. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. PNAS 110:4009-14
23. Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, et al. 2014. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. PNAS 111:12550-55
24. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, et al. 2014. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343(6166):72-76
25. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, et al. 2013. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Investig. 123:855-65
26. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, et al. 2012. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337:1231-35
27. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, et al. 2013. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet. 45:1141-49
28. Schonberg DL, Bao S, Rich JN. 2013. Genomics informs glioblastoma biology. Nat. Genet. 45:1105-7
29. AkhavanD,Pourzia AL, Nourian AA, WilliamsKJ, NathansonD, et al. 2013. De-repression ofPDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 3:534-47
30. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, et al. 2014. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343:72-76
31. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, et al. 2012. Differential sensitivity of gliomaversus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2:458-71
32. Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, et al. 2013. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat. Genet. 45:253-61
33. Rheinbay E, Suva ML,Gillespie SM,WakimotoH, Patel AP, et al. 2013. An aberrant transcription factor network essential forWnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 3:1567-79
34. Suva ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, et al. 2014. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157:580-94
35. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, et al. 2015. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348(6238):1036-39
36. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, et al. 2012. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226-31
37. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, et al. 2012. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709-22
38. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, et al. 2014. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet. 46:444-50
39. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-12
40. Ohgaki H, Kleihues P. 2011. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 28:177-83
41. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Cosper AK, et al. 2011. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: Chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J. Neuropathol. Exp. Neurol. 70:110-15
42. JuratliTA, KirschM, Robel K, Soucek S, Geiger K, et al. 2012. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J. Neuro-Oncol. 108:403-10
43. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, et al. 2012. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194-203
44. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, et al. 2012. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol. 124:615-25
45. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, et al. 2015. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 129:133-46
46. AbedalthagafiM, Phillips JJ, Kim GE, Mueller S,Haas-Kogen DA, et al. 2013. The alternative lengthening of telomere phenotype is significantly associated with loss ofATRXexpression in high-grade pediatric and adult astrocytomas: A multi-institutional study of 214 astrocytomas. Mod. Pathol. 26:1425-32
47. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, et al. 2013. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 126:907-15
48. Fontebasso AM, Schwartzentruber J, Khuong-Quang DA, Liu XY, Sturm D, et al. 2013. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 125:659-69
49. Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, et al. 2013. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J. Clin. Oncol. 31:e233-36
50. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, et al. 2011. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453-55
51. Yip S, Butterfield YS, Morozova O, Chittaranjan S, BloughMD, et al. 2012. Concurrent CICmutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J. Pathol. 226:7-16
52. Badiali M, Gleize V, Paris S, Moi L, Elhouadani S, et al. 2012. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol. 22:841-47
53. Kim YH, Nonoguchi N, Paulus W, Brokinkel B, Keyvani K, et al. 2012. Frequent BRAF gain in lowgrade diffuse gliomas with 1p/19q loss. Brain Pathol. 22:834-40
54. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, et al. 2013. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 45:602-12
55. Cruz GR, Dias Oliveira I, Moraes L, Del Giudice Paniago M, de Seixas Alves MT, et al. 2014. Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. J. Neuro-Oncol. 117:235-42
56. Nakamura M, Shimada K, Ishida E, Higuchi T, Nakase H, et al. 2007. Molecular pathogenesis of pediatric astrocytic tumors. Neuro-Oncology 9:113-23
57. Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry A, et al. 2008. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 27:4745-51
58. Hoischen A, Ehrler M, Fassunke J, Simon M, BaudisM, et al. 2008. Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH. Brain Pathol. 18:326-37
59. Jacob K, Albrecht S, Sollier C, Faury D, Sader E, et al. 2009. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br. J. Cancer 101:722-33
60. Pfister S, Janzarik WG, Remke M, Ernst A,Werft W, et al. 2008. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Investig. 118:1739-49
61. Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, et al. 2009. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 19:449-58
62. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, et al. 2009. Activation of the ERK/MAPK pathway: A signature genetic defect in posterior fossa pilocytic astrocytomas. J. Pathol. 218:172-81
63. Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, et al. 2012. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J. Neuropathol. Exp. Neurol. 71:66-72
64. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. 2009. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28:2119-23
65. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, et al. 2011. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism ofMAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 121:763-74
66. JonesDT, Hutter B, Jager N, Korshunov A,Kool M, et al. 2013. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 45:927-32
67. Sharma MK, Zehnbauer BA, Watson MA, Gutmann DH. 2005. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 65:1335-36
68. Janzarik WG, Kratz CP, Loges NT, Olbrich H, Klein C, et al. 2007. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 38:61-63
69. DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, et al. 1992. Abnormal regulation ofmammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-73
70. Tatevossian RG, Tang B, Dalton J, Forshew T, Lawson AR, et al. 2010. MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol. 120:731-43
71. Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, et al. 2013. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. PNAS 110:8188-93
72. JonesC, Baker SJ. 2014. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat. Rev. Cancer 14:551-61
73. Roujeau T, Machado G, Garnett MR, Miquel C, Puget S, et al. 2007. Stereotactic biopsy of diffuse pontine lesions in children. J. Neurosurg. 107:1-4
74. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, et al. 2012. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44:251-53
75. SturmD,WittH,Hovestadt V, Khuong-Quang DA, JonesDT, et al. 2012. Hotspot mutations inH3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-37
76. Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, et al. 2013. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 3:512-19
77. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, et al. 2014. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46:451-56
78. Taylor KR,Mackay A, Truffaux N, ButterfieldYS, Morozova O, et al. 2014. Recurrent activatingACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet. 46:457-61
79. FontebassoAM,Papillon-Cavanagh S, Schwartzentruber J,NikbakhtH,GergesN, et al. 2014. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat. Genet. 46:462-66
80. Lee J, Son MJ, Woolard K, Donin NM, Li A, et al. 2008. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13:69-80
81. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, et al. 2006. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444:761-65
82. Paugh BS, Qu C, JonesC, Liu Z, Adamowicz-Brice M, et al. 2010. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28:3061-68
83. Baylin SB, Jones PA. 2011. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11:726-34
84. Dawson MA, Kouzarides T. 2012. Cancer epigenetics: From mechanism to therapy. Cell 150:12-27
85. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, et al. 2014. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506:445-50
86. Suva ML, Riggi N, Bernstein BE. 2013. Epigenetic reprogramming in cancer. Science 339:1567-70
87. SturmD, Bender S, Jones DT,Lichter P,Grill J, et al. 2014. Paediatric and adult glioblastoma:Multiform (epi)genomic culprits emerge. Nat. Rev. Cancer 14:92-107
88. Mazor T, Pankov A, Johnson BE, Hong C, Hamilton EG, et al. 2015. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28(3):307-17
89. Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, et al. 2015. EGFR mutation promotes glioblastoma through epigenome and transcription factor network remodeling. Mol. Cell 60(2):307-18
90. de Vries NA, Hulsman D, Akhtar W, de Jong J, Miles DC, et al. 2015. Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression. Cell Rep. 10:383-97
91. Losman JA, Kaelin WG Jr. 2013. What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27:836-52
92. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360:765-73
93. Turcan S, Rohle D, Goenka A,Walsh LA, Fang F, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-83
94. Dang L, WhiteDW, Gross S, Bennett BD, Bittinger MA, et al. 2009. Cancer-associated IDH1mutations produce 2-hydroxyglutarate. Nature 462:739-44
95. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-67
96. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, et al. 2010. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839-43
97. Kim YH, Pierscianek D, Mittelbronn M, Vital A, Mariani L, et al. 2011. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J. Clin. Pathol. 64:850-52
98. Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, et al. 2016. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529:110-14
99. Wick W, WellerM, van den BentM, SansonM,WeilerM, et al. 2014.MGMTtesting-The challenges for biomarker-based glioma treatment. Nat. Rev. Neurol. 10:372-85
100. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, et al. 2012. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol. 13:707-15
101. Cancer Genome Atlas Res. Netw. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-68
102. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
103. Yuen BT, Knoepfler PS. 2013. Histone H3.3 mutations: A variant path to cancer. Cancer Cell 24:567-74
104. Jenuwein T, Allis CD. 2001. Translating the histone code. Science 293:1074-80
105. Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, et al. 2013. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340:857-61
106. Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, et al. 2013. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol. 23:558-64
107. HerzHM,MorganM,Gao X, Jackson J,RickelsR, et al. 2014. HistoneH3 lysine-to-methioninemutants as a paradigm to study chromatin signaling. Science 345:1065-70
108. Chan KM, Fang D, Gan H, Hashizume R, Yu C, et al. 2013. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 27:985-90
109. Suva ML, Riggi N, JaniszewskaM, Radovanovic I, Provero P, et al. 2009. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69:9211-18
110. Funato K, Major T, Lewis PW, Allis CD, Tabar V. 2014. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 346:1529-33
111. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, et al. 2014. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med. 20:1394-96
112. Grasso CS, Tang Y, TruffauxN, BerlowNE, Liu L, et al. 2015. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21(6):555-59
113. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, et al. 2012. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307:1062-71
114. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-78
115. Kreso A, Dick JE. 2014. Evolution of the cancer stem cell model. Cell Stem Cell 14:275-91
116. Meacham CE, Morrison SJ. 2013. Tumour heterogeneity and cancer cell plasticity. Nature 501:328-37
117. Nguyen LV, Vanner R, Dirks P, Eaves CJ. 2012. Cancer stem cells: An evolving concept. Nat. Rev. Cancer 12:133-43
118. Bao S,Wu Q, McLendon RE, Hao Y, Shi Q, et al. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-60
119. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, et al. 2009. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780-83
120. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, et al. 2010. A hierarchy of selfrenewing tumor-initiating cell types in glioblastoma. Cancer Cell 17:362-75
121. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. 2008. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40:499-507
122. Lathia JD, Mack SC,Mulkearns-Hubert EE, Valentim CL, Rich JN. 2015. Cancer stem cells in glioblastoma. Genes Dev. 29(12):1203-17
123. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, et al. 2010. TGF-βreceptor inhibitors target theCD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell 18:655-68
124. Chen J, Li Y, Yu TS, McKay RM, Burns DK, et al. 2012. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522-26
125. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, et al. 2010. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6:421-32
126. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. 2004. Identification of human brain tumour initiating cells. Nature 432:396-401
127. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. 2009. SSEA-1 is an enrichment marker for tumorinitiating cells in human glioblastoma. Cell Stem Cell 4:440-52
128. Stricker SH, Feber A, Engstrom PG, Caren H, Kurian KM, et al. 2013. Widespread resetting of DNA methylation in glioblastoma-initiating cells suppressesmalignant cellular behavior in a lineage-dependent manner. Genes Dev. 27:654-69
129. Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, et al. 2015. Preferential iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell 28(4):441-55
130. Hitomi M, Deleyrolle LP, Mulkearns-Hubert EE, Jarrar A, Li M, et al. 2015. Differential connexin function enhances self-renewal in glioblastoma. Cell Rep. 11(7):1031-42
131. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, et al. 2013. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154:61-74
132. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, et al. 2010. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-94
133. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, et al. 2012. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338:1080-84
134. Holland EC, Hively WP, DePinho RA, Varmus HE. 1998. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 12:3675-85
135. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, et al. 2011. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146:209-21
136. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, et al. 2011. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17:1086-93
137. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. 2010. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-17
138. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, et al. 2014. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396-401
139. Jeuken JW, von Deimling A, Wesseling P. 2004. Molecular pathogenesis of oligodendroglial tumors. J. Neuro-Oncol. 70:161-81
140. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, et al. 1995. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int. J. Cancer 64:207-10
141. Kraus JA, Koopmann J, Kaskel P,Maintz D, Brandner S, et al. 1995. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J. Neuropathol. Exp. Neurol. 54:91-95
142. Bax DA, Mackay A, Little SE, Carvalho D, Viana-Pereira M, et al. 2010. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin. Cancer Res. 16:3368-77
143. Neumann E, Kalousek DK, Norman MG, Steinbok P, Cochrane DD, Goddard K. 1993. Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet. Cytogenet. 71:40-49
144. White FV, Anthony DC, Yunis EJ, Tarbell NJ, Scott RM, Schofield DE. 1995. Nonrandom chromosomal gains in pilocytic astrocytomas of childhood. Hum. Pathol. 26:979-86
145. Zattara-Cannoni H, Gambarelli D, Lena G, Dufour H, Choux M, et al. 1998. Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet. Cytogenet. 104:157-60